Clinical Trials - March 19, 2019
Preclinical data from Alligator demonstrate strong anti-tumor effects
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal antibody in development for the treatment of metastasizing cancer. It activates the co-stimulatory receptor 4-1BB and its immuno-stimulatory function is dependent on cross-linking to Fc-gamma […]
Listing - November 29, 2016
Trading of Alligator on Nasdaq has begun
Alligator Bioscience has started trading of its shares on the main market of Nasdaq Stockholm. Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies and is primarily active in the early phases of drug development, from the idea stage to clinical phase II trials. […]